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Abstract 
Purpose: The most aggressive form of skin cancer is the malignant melanoma. Because of its high 
metastatic potential the early detection of primary melanoma tumors and metastases using 
non-invasive PET imaging determines the outcome of the disease. Previous studies have already 
shown that benzamide derivatives, such as procainamide (PCA) specifically bind to melanin 
pigment. The aim of this study was to synthesize and investigate the melanin specificity of the novel 
68Ga-labeled NODAGA-PCA molecule in vitro and in vivo using PET techniques.  
Methods: Procainamide (PCA) was conjugated with NODAGA chelator and was labeled with 
Ga-68 (68Ga-NODAGA-PCA). The melanin specificity of 68Ga-NODAGA-PCA was tested in vitro, 
ex vivo and in vivo using melanotic B16-F10 and amelanotic Melur melanoma cell lines. By 
subcutaneous and intravenous injection of melanoma cells tumor-bearing mice were prepared, on 
which biodistribution studies and small animal PET/CT scans were performed for 
68Ga-NODAGA-PCA and 18FDG tracers. 
Results: 68Ga-NODAGA-PCA was produced with high specific activity (14.9±3.9 GBq/µmol) and 
with excellent radiochemical purity (98%<), at all cases. In vitro experiments showed that 
68Ga-NODAGA-PCA uptake of B16-F10 cells was significantly (p≤0.01) higher than Melur cells. Ex 
vivo biodistribution and in vivo PET/CT studies using subcutaneous and metastatic tumor models 
showed significantly (p≤0.01) higher 68Ga-NODAGA-PCA uptake in B16-F10 primary tumors and 
lung metastases in comparison with amelanotic Melur tumors. In experiments where 18FDG and 
68Ga-NODAGA-PCA uptake of B16-F10 tumors was compared, we found that the 
tumor-to-muscle (T/M) and tumor-to-lung (T/L) ratios were significantly (p≤0.05 and p≤0.01) 
higher using 68Ga-NODAGA-PCA than the 18FDG accumulation. 
Conclusion: Our novel radiotracer 68Ga-NODAGA-PCA showed specific binding to the melanin 
producing experimental melanoma tumors. Therefore, 68Ga-NODAGA-PCA is a suitable 
diagnostic radiotracer for the detection of melanoma tumors and metastases in vivo. 
Key words: B16-F10 tumor; 18FDG; 68Ga-NODAGA-PCA; Melanoma malignum; Positron Emission 
Tomography, Procainamide. 
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Introduction 
Melanoma malignum is an aggressive form of 
skin cancers that originates from melanocytes. Its 
incidence has rapidly increased in the last decades [1]. 
Despite continuous screening programs for the early 
detection and excision of the primary tumor, the 
number of patients and those in advanced stages of 
the disease increase over time. The aggressiveness of 
melanomas stems from their ability to rapidly grow 
towards local capillaries and then to form distant 
metastases in several organs (e.g.: lungs, brain, 
kidneys, liver, and intestines) even when the primary 
tumor is small [2]. The presence of melanoma 
metastases largely reduces the length of survival (the 
5-years survival rate is between 5-19%) [3], therefore 
the early identification and localization of these 
metastases is crucial for patient survival, wherein 
medical imaging techniques play pivotal role [4,5].  
Among the non-invasive imaging techniques 
positron emission tomography (PET) is a useful 
method for the detection and staging of malignances 
due to its high sensitivity and resolution [6]. The most 
commonly used radiotracer for imaging primary 
tumors and metastases is the 
18F-Fluoro-2-deoxy-D-glucose (18FDG) [7]. 18FDG is a 
glucose analogue that accumulates in cells 
characterized by high metabolic activity such as 
tumors. Despite the widespread use 18FDG has certain 
limitations: it is not specific for malignant melanoma, 
moreover, it is also taken up by inflammatory lesions 
and the cells of the central nervous system making the 
distinction between healthy and diseased tissue on 
PET images difficult [8,9]. These limitations of 18FDG 
calls for the synthesis and characterization of 
melanoma-specific tracers that do not accumulate in 
metabolically active tissues, only in the tumors. 
In this study we presented the synthesis and the 
characterization of a new procainamide-derivative 
NODAGA-PCA labeled with 68Ga to be used as a 
melanin-specific PET-tracer. Procainamide (PCA) is 
the derivative of 4-aminobenzoic acid and it is used 
for the treatment of cardiac arrhythmias [10,11]. It has 
been reported that benzamide derivatives (e.g.: 
procainamide) specifically bind to melanin [12-15]. 
Several studies reported that 18F-labeled benzamide 
analogues, among others 18F-FPBZA 
([18F]N-(2-diethylaminoethyl)-4-[2-(2-(2-fluoroetoxy)e
thoxy]benzamide [15], 18F-DAFBA 
(N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide 
[16], 18F-5-FPN 
(18F-5-Fluoro-N-(2-[diethyamino]ethyl)picolamide 
[17] are promising radiotracers for the in vivo imaging 
of malignant melanoma. However, the preparation of 
these 18F-labeled radiopharmaceuticals is limited 
because cyclotron is required for the production of 18F. 
Generator-based radioisotopes are convenient 
alternatives to cyclotron produced 11C and 18F [18-20]. 
The PET-isotope, 68Ga bears close to ideal physical 
properties (89% β+; t1/2 = 67.7 min; Eav(β+) = 740 keV), 
easy, on-site accessibility via commercially available 
68Ge/68Ga-generators. Additionally, the conjugation 
of 68Ga to small, biocompatible molecules is a 
well-established method and rapidly growing field 
with numerous applications to modern 
radiopharmaceutical chemistry [21]. The commonly 
applied macrocyclic chelators other than DOTA with 
the ability to efficiently chelate trivalent gallium-ion at 
room temperature – such as NOTA or NODAGA – 
can prevent the utilization of elevated temperature 
which is detrimental in case of thermally unstable 
precursors. 
The aim of this study was to characterize the 
biological behavior of 68Ga-NODAGA-PCA 
noninvasively. To attest the melanin specificity of this 
radiopharmaceutical, in vitro and in vivo experiments 
were performed using amelanotic Melur and melanin 
containing B16-F10 melanoma cells lines. To confirm 
the tumor specificity of 68Ga-NODAGA-PCA in vivo, 
subcutaneous and pulmonary metastatic animal 
models were investigated using small animal imaging 
techniques (miniPET/CT). 
Materials and Methods 
Chemicals 
All commercially available chemicals were of 
analytical grade and used without further 
purification. For the radiolabeling studies, TraceSelect 
Ultra water - Sigma-Aldrich Kft. (Budapest, Hungary) 
– Ultrapur HCl and Suprapur NaOH*H2O were 
obtained from Merck Kft. (Budapest, Hungary). 
Procainamide hydrochloride and all other chemicals 
were the product of Sigma-Aldrich Kft. (Budapest, 
Hungary), if not specifically stated otherwise. 
NODAGA-NHS ester was purchased from 
Chematech (Dijon, France). 
Conjugation reaction of 4-Amino-N-(2- 
diethylaminoethyl) benzamide hydrochloride 
with NODAGA-NHS ester 
27.2 mg (100 µmol) from the 4-Amino-N- 
(2-diethylaminoethyl)benzamide hydrochloride was 
dissolved in 2 mL of acetonitrile (MeCN) / 0.1 M 
sodium carbonate buffer (pH 9.5) 3:1. 69.5 mg (95 
µmol) of NODAGA-NHS ester was introduced into 
the mixture. The pH was adjusted between 8.5 and 9 
by means of 2% of NaOH and the mixture was stirred 
for 2 h at room temperature. The resulting NODAGA- 
conjugated benzamide-analogue (NODAGA-PCA) 
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was purified by means of semi-preparative RP-HPLC 
and the collected fractions were lyophilized. The pure 
product was characterized by analytical RP-HPLC (as 
described below), ESI-MS (Shimadzu LCMS IT-TOF 
Mass Spectrometer, Shimadzu Corp., Tokyo, Japan) 
and 1H-NMR (Bruker WP 360 SY). 
Radiolabeling of NODAGA-PCA with Ga-68 
We have performed the optimization of the 
radiosynthesis both at room- and at elevated 
temperature. Due to our compound proved to be not 
heat-sensitive and the higher temperature granted 
higher specific activity, therefore for the animal 
experiments we have produced the radiotracer 
exclusively at 95ºC. This labeling protocol is based on 
the procedure described by Wängler et al. [22]. 
68Ge/68Ga-generator (Obninsk, Eckert & Ziegler, 
Germany) was eluted with 0.1 M HCl (aq). A fraction 
of 1 mL volume containing the highest activity (≈ 
350 MBq) was collected, buffered with sodium-acetate 
(1M; 0.15 mL, aq.) and the pH of the stock solution 
was adjusted to ~ 4.5 by the addition of NaOH (2 %, 
0.06 mL, aq.). Then, 5 µL of a 3 mM NODAGA-PCA 
stock-solution was added and the mixture was 
incubated for 5 min at 95ºC. Afterwards, the reaction 
mixture was transferred onto a preactivated Oasis 
HLB 1 cc cartridge (30 mg sorbent). After 
immobilization of the radioactivity from the mixture, 
the column was washed with 2 mL of water and then 
retained activity was recovered with 0.5 mL isotonic 
NaCl solution/EtOH 2:1. The radiotracer-solution 
was further diluted with 2 mL isotonic NaCl solution 
to decrease the alcohol content below 10 % and it was 
sterile filtered. The specific activity of the product 
varies between 13-18 GBq/µmol. The radiochemical 
purity (%) of the final product was determined by 
application of an analytical RP-HPLC. 
Preparative and analytical RP-HPLC methods 
The purification of the NODAGA-PCA was 
performed on a KNAUER HPLC system using a 
semi-preparative Supelco Discovery® Bio Wide Pore 
C18 column (150 mm x 10 mm; 10 μm diameters), 
with a flow rate of 4.4 mL/min. After a short isocratic 
period (3 min) a linear gradient was used (3 min 0 % 
B; 20 min 50 % B) with eluent A (0.1% TFA in water) 
and eluent B (0.1% TFA in MeCN-H2O (95:5, v/v), 
applying 254 nm for peak detection.  
For the quality control of the radiolabeled 
compound a similar configuration of KNAUER HPLC 
- extended with a radiodetector - was used. For 
analytical purposes a Supelco Discovery® Bio Wide 
Pore C18 column (250 mm x 4.6 mm) 10 μm diameters 
was equipped and 1 mL/min flow rate was applied, 
with a gradient profile: 0 min 0% B, 3 min 0 % B; 20 
min 50 % B. Signals were simultaneously detected by 
radiodetector and UV detector (254 nm). 
Determination of partition coefficient of 
68Ga-NODAGA-PCA 
The partition coefficient of 68Ga-NODAGA-PCA 
was expressed as logP by measuring the distribution 
of radioactivity in 1-octanol and PBS-solution (pH 
=7.4). Approximately 1.5 MBq of 68Ga-NODAGA- 
PCA in 10 µL aq. solution was added to an 
Eppendorf-vial containing 0.5 mL of PBS and 0.5 mL 
of 1-octanol. After vigorously vortexing of the mixture 
for 20 min, the vial was centrifuged at 20.000 rpm for 
5 min in order to reach complete separation of layers. 
100 µL of each layer was transferred into test tubes; 
the radioactivity was measured with a gamma 
counter (Perkin-Elmer Packard Cobra, Waltham, MA, 
USA). LogP value was determined from the results of 
six experiments. 
Determination of in vitro stability of 
68Ga-NODAGA-PCA 
The stability of 68Ga-NODAGA-PCA was tested 
in mouse serum at 37ºC. Approximately 8 MBq of 
68Ga-NODAGA-PCA was introduced into mouse 
serum and was incubated. For serum stability study, 
50 µL aliquot of 68Ga-NODAGA-PCA at various time 
points (0, 30, 60, 90 and 120 min) was mixed with 
50 µL cold abs. EtOH. Precipitate was pelleted by 
centrifugation at 20.000 rpm for 5 min. The 
supernatant was collected, further diluted with water 
and the radiochemical purity of 68Ga-NODAGA-PCA 
was determined by means of the analytical RP-HPLC. 
Cell culture 
B16-F10 (mouse melanotic melanoma) and 
Melur (human amelanotic melanoma) cell lines were 
purchased from the American Type Culture 
Collection (ATCC). Cells were grown in Dulbecco's 
Modified Eagle Medium (DMEM High Glucose - 
GlutaMAXTM - Pyruvate) supplemented with 10% 
fetal bovine serum (FBS), 1% non-essential amino acid 
solution (Sigma Aldrich, cat.: M7145) and 1% MEM 
vitamin solution (Sigma Aldrich) at regular conditions 
(5% CO2, 37 °C). 
For the in vitro studies and animal experiments 
the cells were used after 6-8 passages and 80% 
confluence at T75 culture flasks. The viability of the 
cells used in our experiments was always higher than 
90%, as assessed by the trypan blue exclusion test. 
In vitro 68Ga-NODAGA-PCA uptake and efflux 
studies  
B16-F10 and Melur cells were trypsinized, 
centrifuged and resuspended in PBS containing 1 mM 
glucose (gl-PBS). The samples were preincubated at 
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37 °C for 10 min at a cell concentration of 1 × 106 ml−1 
in gl-PBS. 0.37 MBq/ml 68Ga-NODAGA-PCA was 
then added to each sample. After the addition of the 
radiotracer, cells were further incubated at 37 °C for 
30 and 90 min. After the incubation time, samples 
were washed 3 times with ice-cold PBS and 
resuspended in 1 ml of ice cold PBS. Afterwards, 
radioactivity was measured with Canberra Packard 
gamma-counter for 1 min within the 68Ga-sensitive 
energy window. 
For the investigation of 68Ga-NODAGA-PCA 
efflux the samples were first loaded with 
68Ga-NODAGA-PCA (at 37 °C for 30 and 90 min) and 
then washed with gl-PBS at room temperature. 
Subsequent centrifugation the supernatant was 
removed and the cells were resuspended in 2 ml 37°C 
gl-PBS and further incubated for 10 min at 37 °C. The 
efflux was terminated by the addition of ice-cold PBS. 
The cells were then washed twice with ice cold PBS 
and the radioactivity was measured in the 
gamma-counter for 1 min within the 68Ga-sensitive 
energy window. Decay-corrected radiotracer uptake 
was expressed as counts min−1 (106 cells)−1 (cpm). The 
displayed data represents the means of at least three 
independent experiments (± SD) carried out using 
different cell passages, and each experiment was 
performed in triplicate. 
In vivo tumor models 
For the establishment of melanoma tumor 
models adult female C57BL/6 (n=25) and CB17 SCID 
(n=20) (from Charles River Laboratories by Innovo 
Kft., Hungary) were used at 8-10 weeks of age. To 
generate lung-metastasis and subcutaneous tumors, 
C57BL/6 mice were injected with 1x105 B16-F10 
tumor cells in 0.9% NaCl (100 µl) intravenously or 
subcutan into the left shoulder area. For the induction 
of amelanotic tumor model CB17 SCID mice were 
used; 1x105 amelanotic Melur tumor cells in 100 µl 
saline were injected into the left shoulder area of SCID 
mice. The growth of subcutaneous tumors was 
assessed by caliper measurements and tumor size was 
calculated using the following formula: (largest 
diameter x smallest diameter2)/2. In vivo experiments 
were carried out approximately 20 days after 
intravenous and subcutaneous injection of tumor cells 
at the tumor volume of 100-120 mm3. 
Animal PET/CT imaging 
Control and tumor-bearing animals were 
injected with 7.0±0.2 MBq of 68Ga-NODAGA-PCA or 
18FDG via the tail vein 20±2 days after the 
implantation of B16-F10 or Melur cells. 90 min after 
68Ga-NODAGA-PCA and 60 min after 18FDG injection 
mice were anaesthetized by 3% isoflurane (Forane) 
with a dedicated small animal anesthesia device and 
whole body PET scans (10 min acquisition time) were 
acquired using the MiniPET-II scanner [23]. Scanner 
normalization and random correction were applied 
on the data and the images were reconstructed with 
the standard EM iterative algorithm. The voxel size 
was 0.5x0.5x0.5 mm and the spatial resolution varies 
between 1.4 to 2.1 mm from central to 25 mm radial 
distances. For the anatomical localization of organs 
and tumors cone-beam computer tomography (CBCT, 
3D Accuitomo, Japan) scans were used as we 
described earlier [24]. Briefly, the X-ray tube settings 
were voltage 60 kVp, current 8.0 µA, and exposure 
time 30.8 s per projection; voxel size: 160 µm. 
Quantitative PET data analysis 
Quantitative radiotracer uptake was expressed 
in terms of standardized uptake value (SUV), SUV = 
[VOI activity (Bq/mL)]/[injected activity (Bq)/animal 
weight (g)], assuming a density of 1 g/mL. Volumes 
of interest (VOI) were manually drawn around the 
edge of the organ or tumor activity by BrainCad 
software [24]. Tumor-to-muscle (T/M) and 
tumor-to-lung (T/L) ratios were computed as the 
ratio between the activity in the tumor VOI and in the 
background (muscle or lung) VOI. Healthy lung from 
control mouse was used for the calculation of T/L 
ratio. 
Ex vivo biodistribution studies 
One day after in vivo imaging studies, animals 
were injected intravenously with 7.0±0.2 MBq of 
68Ga-NODAGA-PCA or 18FDG. Mice were euthanized 
with 5% isoflurane 90 and 60 min after the injection of 
68Ga-NODAGA-PCA and 18FDG, respectively. As we 
described earlier, tissue samples were taken from each 
organ and their weight and radioactivities were 
measured with gamma counter and DAR (Differential 
Absorption Ratio) values were calculated [24]. 
Data analysis 
Significance was calculated by Mann-Whitney 
U-test and the signiﬁcance level was set at p≤0.05 
unless otherwise indicated. Data are presented as 
mean±SD of at least three independent experiments. 
Results 
Chemical and radiochemical synthesis 
The NODAGA-PCA was prepared by a 
conjugation reacting between 4-Amino-N-(2-diethy-
laminoethyl)benzamide hydrochloride and 
NODAGA-NHS ester (Fig 1.). The purity of 
NODAGA-PCA was more than 99% after 
semi-preparative RP-HPLC. 1H-NMR (DMSO d-6)δ = 
1.27-1.32 (t, 6H), 2.05-2.25 (m, 2H), 2.65-2.68 (t, 2H), 
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3.07-3.1 (m, 4H), 3.15-3.25 (m, 8H), 3,28-3,32 (m, 4H), 
3.35-3.42 (m, 2H), 3.6-3.65 (t, 1H), 3.7-3.85 (m, 6H), 
7.55-7.65 (d, 2H), 7.75-7.85 (d, 2H). The purified 
product was identified by ESI-MS also and found it 
[M + H]+=593.32 as calculated. The analysis of the MS 
spectrum verified the expected structure. The overall 
synthesis time of 68Ga-NODAGA-PCA was 15 min. 
including the reformulation. The average 
decay-corrected yield was 68.1±6.7% (n=7) and the 
radiochemical purity exceeded 98% in every case. The 
specific activity of the radiotracer was 14.95±3.9 
GBq/µmol. 
 
 
Figure 1. The reaction scheme of the chemical synthesis of NODAGA-PCA. 
 
Partition coefficient and in vitro stability of 
68Ga-NODAGA-PCA 
The partition coefficient (logP) of 
68Ga-NODAGA-PCA was determined to be 
-2.79±0.10, suggesting that the radiotracer is highly 
hydrophilic. Moreover, the stability of the labeled 
molecule was measured in mouse serum at 37ºC using 
analytical radio-HPLC. After 2 hours of incubation in 
mouse serum, more than 95 % of the original labeled 
compound remained intact. These latter results 
suggest a highly stable molecule under the applied 
conditions. 
In vitro uptake and efflux studies 
The melanin specificity of 68Ga-NODAGA-PCA 
was investigated under in vitro conditions using 
melanin positive B16-F10 and melanin negative Melur 
cell lines. After 30 and 90 min incubation time 
significant (p≤0.01) differences were observed 
between the melanin positive (1.66±0.43 at 30 min; 
2.60±0.72 at 90 min) and negative (0.12±0.04 at 30 min; 
0.14±0.06 at 90 min) cell lines (Fig. 2). In the efflux 
studies significant (p≤0.01) differences were also 
found between the tracer accumulation of melanin 
positive and negative cell lines. In these washout 
experiments, cells were first loaded with 
68Ga-NODAGA-PCA, followed by extensive washing 
rounds, and then cells were further incubated for 10 
min without radioactivity. The melanin-containing 
B16-F10 cell line showed significantly higher 
68Ga-NODAGA-PCA content at both time points 
(0.78±0.15 at 30 min; 1.42±0.43 at 90 min) than the 
melanin-negative Melur cell line (0.08±0.04 at 30 min; 
0.08±0.02 at 90 min) (Fig. 2). The radiotracer content in 
B16-F10 cell line was approximately 13-fold higher at 
30 min and 18-fold higher at 90 min than in Melur 
cells. These differences did not change considerably 
with the efflux, after 30 and 90 min incubation time 
followed by 10 min efflux, the radiotracer uptake of 
B16-F10 cells were 9-fold higher at 30 min and 17-fold 
higher at 90 min than amelanotic Melur cells. 
 
 
Figure. 2. Comparison of time dependent in vitro 68Ga-NODAGA-PCA uptake 
and efflux (washout kinetic) of melanotic (B16-F10) and amelanotic (Melur) 
melanoma cell lines. Significance level: p≤0.01 (**). The displayed data are the 
means ± SD of the results of at least three independent experiments, each 
performed in triplicate. 
 
In vivo and ex vivo biodistribution studies in 
healthy animals 
In vivo imaging and ex vivo biodistribution 
studies were performed using healthy C57BL/6 
mouse as controls. 90 min after the injection of 7.0±0.2 
MBq of 68Ga-NODAGA-PCA the biodistribution was 
evaluated by whole body miniPET scans. 
Representative decay-corrected coronal miniPET/CT 
image is shown in Fig. 3A. In control animals low 
accumulation was observed in the abdominal organs 
and tissues (liver, spleen, intestines) and in the 
thoracic region. The urinary system (kidneys and 
urine) were clearly visualized 90 min after tracer 
injection (Fig. 3A). 
These in vivo miniPET/CT biodistribution results 
correlated well with the ex vivo data summarized in 
Fig. 3B. For the ex vivo organ and tissue distribution 
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studies the animals were sacrificed 90 min after the  
68Ga-NODAGA-PCA injection, dissected, and the 
accumulated activities of the tissues and organs were 
counted with gamma counter. 90 min after the 
injection of 68Ga-NODAGA-PCA the DAR values of 
kidneys (0.51±0.19) and urine (53±8.24) showed high 
tracer accumulation in control mice. In contrast, very 
low tracer uptake was measured in the liver 
(0.07±0.02), intestines (0.04±0.01), spleen (0.03±0.01), 
stomach (0.03±0.01), lung (0.02±0.01) and muscle 
(0.01±0.005). 
In vivo and ex vivo biodistribution studies on 
subcutaneous tumor models 
The melanin specificity of 68Ga-NODAGA-PCA 
was investigated by in vivo and ex vivo studies using 
subcutaneously growing melanotic B16-F10 and 
amelanotic Melur tumors 20±2 days after tumor cell 
inoculation. 
Decay-corrected representative axial images of 
experimental melanoma tumors are shown on Fig. 4. 
B16-F10 tumors were clearly visualized with the 
melanin specific 68Ga-NODAGA-PCA 90 min after the 
tracer injection (Fig. 4B and C). After the quantitative 
analysis of PET images significant differences (at 
p≤0.01 level) were found in the SUV values of the 
investigated B16-F10 and Melur tumors. The 
SUVmean, SUVmax, T/M SUVmean and T/M 
SUVmax values of the melanin producing B16-F10 
tumors were 0.35±0.09, 2.03±0.87, 11.3±2.28 and 
13.99±3.25, respectively. Additionally, these values 
were significantly higher (p≤0.01) than the tracer 
uptake of amelanotic Melur tumors, where the 
SUVmean, SUVmax, T/M SUVmean and T/M 
SUVmax values were 0.07±0.03, 0.30±0.06, 1.12±0.25 
and 0.97±0.14, respectively, confirming the melanin 
binding specificity in vivo (Fig. 4G). 
To investigate the melanin specificity of 
68Ga-NODAGA-PCA in subcutaneously growing 
B16-F10 and amelanotic Melur tumors, we performed 
ex vivo biodistribution studies at 90 min post injection. 
Table 1 demonstrates that the 68Ga-NODAGA-PCA 
uptake of B16-F10 tumor was significantly (p≤0.01(**)) 
higher than that of Melur tumor. This approximately 
thirty-fold higher accumulation in B16-F10 melanoma 
confirmed the melanin binding specificity of the 
radiotracer ex vivo. By taking the tumor-to-muscle 
(background) ratios, the difference between the two 
tumors was also significant at p≤0.01 (Table 1). 
 
Table 1. 68Ga-NODAGA-PCA uptake (DAR) in s.c. B16-F10 and 
Melur tumors 90 min after tracer injection and 20±2 days after 
tumor cell inoculation. Significance level between B16-F10 and 
Melur data: p≤0.01 (**). 
Organ/tissue B16-F10 (n=5) Melur (n=5) 
Tumor (s.c.) 0.31 ± 0.04** 0.01 ± 0.01 
Tumor/muscle 16.86 ± 3.14** 1.29 ± 0.31 
 
 
 
Figure 3. In vivo and ex vivo biodistribution data for 68Ga-NODAGA-PCA. A: Representative coronal miniPET/CT image of healthy control C57BL/6 mouse 90 min 
after the radiotracer injection. Yellow arrow: liver; red arrows: kidneys; white arrow: bladder with urine. B: quantitative analysis of tracer uptake in control animals 
(n=5) 90 min after the injection of 68Ga-NODAGA-PCA. DAR values are presented as mean±SD. 
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Figure 4. Comparison of in vivo accumulation of 68Ga-NODAGA-PCA in B16-F10 (A-C) and Melur (D-F) tumors 90 min after the tracer injection. Representative 
axial CT (A, D), miniPET (B, E) and miniPET/CT (C, F) images of the subcutaneously growing melanin positive B16-F10 (red arrows) and amelanotic Melur (white 
arrows) tumors. G: quantitative analysis of the in vivo tracer uptake in B16-F10 (n=5) and Melur (n=5) tumors. Insert: 68Ga-NODAGA-PCA uptake ratios of B16-F10 
and Melur tumors. Data are presented as mean ± SD. T/M: Tumor/Muscle ratio. Significance level: p≤0.01 (**). 
 
The accumulation of 68Ga-NODAGA-PCA and 
18FDG in melanoma tumors growing under the skin 
was compared by miniPET scans 90 and 60 min after 
radiotracer injection, respectively (Fig. 5). 
Subcutaneously growing B16-F10 and Melur tumors 
were clearly visualized with the most commonly used 
non-specific 18FDG. By using the melanin specific 
radiotracer 68Ga-NODAGA-PCA, we found high 
accumulation in melanin containing B16-F10 tumors, 
and a good contrasted image with low background 
activity was obtained. In contrast, the melanin 
negative Melur tumors showed very low 
68Ga-NODAGA-PCA accumulation (Fig. 5A). 
After the quantitative analysis of PET images, 
B16-F10 melanoma tumors showed significantly 
(p≤0.01) higher 18FDG uptake (SUVmean: 4.79±0.88, 
SUVmax: 10.35±2.7) than 68Ga-NODAGA-PCA 
accumulation (SUVmean: 0.35±0.09, SUVmax: 
2.03±0.87). In contrast, when the 68Ga-NODAGA-PCA 
uptake data of the tumors were compared to the 
background (muscle) activity, we found that the T/M 
SUVmean and T/M SUVmax were 11.3±2.28 and 
13.99±3.25, respectively. These values were 
approximately two- or three-fold higher than that of 
the 18FDG uptake ratios, where the T/M SUVmean 
and T/M SUVmax values were 5.27±0.81 and 
4.83±1.17, respectively (Fig. 5B). By analyzing the PET 
images of Melur tumors, significantly (p≤0.01) higher 
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18FDG uptake (SUVmean: 0.92±0.10, SUVmax: 
1.51±0.11, T/M SUVmean: 4.42±0.58 and T/M 
SUVmax: 3.27±0.23) was observed than using the 
melanin specific 68Ga-NODAGA-PCA (Fig. 5C). 
In vivo and ex vivo biodistribution studies on 
B16-F10 lung-metastatic tumor model 
The accumulation of 18FDG and 
68Ga-NODAGA-PCA was compared in B16-F10 lung 
metastases by small animal PET scans 20±2 days after 
intravenous injection of tumor cells. Representative 
decay-corrected axial miniPET/CT images of control 
and tumor-bearing mice are shown in Fig. 6. The 
metastatic lesions in the lungs were clearly visualized 
with both radiotracers (Fig. 6B and C). After the 
quantitative analysis of PET images it was found that 
the SUV values of FDG uptake (SUVmean: 2.14±0.7 
and SUVmax: 5.26±1.27) were significantly (p≤0.01) 
higher than that of the melanin specific 
68Ga-NODAGA-PCA uptake (SUVmean: 0.15±0.04, 
SUVmax: 0.42±0.06) (Fig. 6H). However, by analyzing 
the tumor-to-muscle (T/M) and tumor-to-lung (T/L) 
ratios the 68Ga-NODAGA-PCA uptake ratios were 
significantly (p≤0.05 and p≤0.01) higher than the 
18FDG accumulation ratios. 68Ga-NODAGA-PCA 
uptake in B16-F10 lung metastases were 
approximately six- and eight-fold higher than that of 
the lung (T/L SUVmean: 6.66±0.43, T/L SUVmax: 
8.4±0.77) or muscle (T/M SUVmean: 7.66±0.78, T/M 
SUVmax: 8.2±0.94) uptake. By using 18FDG, these 
ratios were lower (T/M SUVmean: 3.32±0.62; T/M 
SUVmax: 4.3±0.68; T/L SUVmean: 2.15±0.21; T/L 
SUVmax: 3.68±0.48) than that of the uptake ratios of 
68Ga-NODAGA-PCA (Fig. 6H). 
 
 
Figure 5. A: Representative axial miniPET images of the same B16-F10 (black arrows) and Melur (red arrows) tumors after the injection of 68Ga-NODAGA-PCA and 
18FDG 20 and 21 days after subcutaneous injection of tumor cells. Red line on CBCT image shows the position of the selected axial slices for PET. White arrow: 
subcutaneously growing Melur tumor. B: quantitative analysis of in vivo radiotracer accumulation in B16-F10 (n=5) tumors 90 and 60 min after 68Ga-NODAGA-PCA 
and 18FDG injection, respectively. C: quantitative analysis of in vivo radiotracer accumulation in amelanotic Melur (n=5) tumors 90 and 60 min after 
68Ga-NODAGA-PCA and 18FDG injection, respectively. Significance level: p≤0.05 (*); p≤0.01 (**). 
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Figure 6. Assessment of 68Ga-NODAGA-PCA and 18FDG uptake in metastatic B16-F10 lesions 20 days after intravenous injection of tumor cells. Upper row: 
Representative axial CT (A), 18FDG-PET/CT (B) and 68Ga-NODAGA-PCA-PET/CT (C) images of the same tumor-bearing mouse. White arrows: metastatic B16-F10 
lesions in the lung. Middle row: Representative axial CT (D), 18FDG-PET/CT (E) and 68Ga-NODAGA-PCA-PET/CT (F) images of a healthy control mouse. Lower row: 
metastatic B16-F10 lesions (white arrows) 20 days after tumor cell injection (G) and quantitative analysis of in vivo tracer uptake data (H) in B16-F10 tumors for 
68Ga-NODAGA-PCA (n=5) and 18FDG (n=5). Significance level: p≤0.05 (*); p≤0.01 (**). 
 
One day after the small animal imaging ex vivo 
biodistribution studies were performed on the same 
animals. The in vivo data correlated with the ex vivo 
results where the B16-F10 tumor-bearing mice were 
sacrificed and dissected 90 or 60 min after the 
injection of 68Ga-NODAGA-PCA or 18FDG, 
respectively. The radiotracer accumulation of the 
tumors, muscle and lung was counted with a 
calibrated gamma counter and DAR values were 
calculated. The autopsy revealed tumorous 
infiltration in the lungs (Fig. 6G). Despite the high 
18FDG and relatively low 68Ga-NODAGA-PCA 
accumulation in the metastatic lung melanoma 
tumors (Table 2), the tumor-to-background (lung, 
muscle) ratios of 68Ga-NODAGA-PCA uptake were 
approximately three-fold higher than in case of 
18FDG. 
 
Table 2. Tracer uptake (DAR) in i.v. induced B16-F10 lung tumors 
20±2 days after tumor cell inoculation. Significance level between 
68Ga-NODAGA-PCA and 18FDG data: p≤0.05 (*); p≤0.01 (**). 
Organ/tissue 68Ga-NODAGA-PCA (n=5) 18FDG (n=5) 
Tumor (B16-F10) 0.16 ± 0.07** 2.12 ± 0.46 
Tumor/Muscle ratio 7.91 ± 1.26* 2.81 ± 0.69 
Tumor/Lung ratio 6.73 ± 1.48* 2.53 ± 0.58 
 
Discussion 
Considering that the incidence rate of malignant 
melanoma is increasing, the clinical and preclinical 
research of this aggressive form of skin cancer is very 
reasonable. The early detection of primary and 
metastatic melanoma lesions using non-invasive 
imaging techniques is critical for the prognosis and 
the outcome of this malignancy [15]. Among in vivo 
functional imaging techniques in nuclear medicine, 
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PET is one of the most sophisticated methods that also 
make it possible to detect tumors and metastases with 
high accuracy and sensitivity [25]. Among 
radionuclides used in molecular imaging, the 
cyclotron independent PET-isotope 68Ga with its 
near-ideal physical properties offers a 
well-established chemistry for the labeling of peptides 
and other small molar-weight biomolecules [20,26,27]. 
In this study we described the synthesis of the 
68Ga-labeled NODAGA-4-Amino-N-(2-diethylami-
noethyl) benzamide (68Ga-NODAGA- 
PCA), which was prepared by the conjugation of 
4-Amino-N-(2-diethylaminoethyl) benzamide 
hydrochloride and NODAGA-NHS ester. The total 
synthesis time was 15 minutes including the final 
formulation providing a convenient synthesis 
timeframe. The radiochemical purity was 98%< and 
the specific activity was approximately 15 GBq/µmol. 
Therefore, this radio-synthesis method enables us to 
produce the melanin specific 68Ga-NODAGA-PCA for 
in vitro and in vivo applications easily with high 
specific activity and radiochemical purity. 
The melanin specificity of 68Ga-NODAGA-PCA 
was investigated under in vitro conditions using 
melanin positive B16-F10 and melanin negative Melur 
cell lines. The 68Ga-NODAGA-PCA uptake in melanin 
containing B16-F10 cells was significantly higher than 
in amelanotic Melur cells at both (30 and 90 min) time 
points. Earlier it was reported that a radiotracer with 
similar chemical structure – namely 
68Ga-SCN-DOTA-PCA accumulated in B16-F10 cells 
in a time-dependent manner [13,14]. Our in vitro 
measurements strengthen this observation, due to it 
was found an increasing accumulation of 
68Ga-NODAGA-PCA in B16-F10 cells, but this 
difference was not significant. Our cellular 
experiments confirmed the melanin binding 
specificity of the 68Ga-NODAGA-PCA. Kim et al. 
[13,14] also found that the radiolabeled benzamide 
derivatives (e.g. 68Ga-SCN-DOTA-PCA, 68Ga-SCN- 
NOTA-BZA) specifically bind to the melanin pigment 
or melanin producing B16-F10 melanoma cells. 
Furthermore, they found elevated radiotracer uptake 
in B16-F10 cells after L-tyrosine (crucial for melanin 
synthesis) treatment. The 68Ga-NODAGA-PCA 
radiotracer uptake in the melanin positive B16-F10 
cell line showed higher values at 30 and 90 min, than 
the reported in vitro cellular uptake of 
68Ga-SCN-DOTA-PCA (0,56%±0,02% at 2h) [14]. In 
addition, we found lower radiotracer uptake in 
B16-F10 cells than it was reported by Ren et al. using 
18F-labeled FBZA (N-[2-(diethylamino)ethyl]-4- 
18F-fluorobenzamide) [28]. After the accumulation 
studies the efflux of 68Ga-NODAGA-PCA was 
investigated in both cell lines. To examine the 
washout kinetics of 68Ga-NODAGA-PCA, B16-F10 
and Melur cells after 30 or 90 incubation times were 
incubated 10 minutes further without radiotracer. We 
found that the 68Ga-NODAGA-PCA content 
decreased after 10 min efflux. It was hypothesized 
that after saturation of melanin-content of the cells, 
the excess radiotracer can remove from the cells. 
Nevertheless, the uptake ratios of melanin positive 
B16-F10 and melanin negative Melur cell lines did not 
differ significantly from the ratio values at 30 and 90 
min accumulation (Fig. 2). Several studies reported 
that the cellular uptake of benzamide derivatives is 
mediated by passive diffusion and it is correlated 
with the logP value [14,16,29-31]. The logP value of 
68Ga-NODAGA-PCA was -2.79±0.10 suggesting that 
the radiotracer is highly hydrophilic. However, Moins 
at al. [29] described that the logP alone is an 
insufficient feature to predict the biological behavior 
of radiolabeled benzamide compound because the 
lower logP value results in lower background in 
tissues, therefore high tumor/background ratio 
values. However, to the actual transport process(es) 
through which benzamide-derivatives enter cells 
needs to be determined in future investigations. 
In vivo and ex vivo biodistribution studies on 
healthy animals demonstrated that the 
68Ga-NODAGA-PCA was mainly excreted from the 
kidney as it was expected by the logP value. The 
accumulation of the radiotracer in other organs was 
low, moderate accumulation was observed after 90 
min incubation time (Fig. 3). These results correlated 
well with other reports where radiolabeled 
benzamides that share structural similarities with 
68Ga-NODAGA-PCA were investigated [13-15,28,29].  
The melanin specificity of 68Ga-NODAGA-PCA 
was investigated by in vivo and ex vivo biodistribution 
studies using subcutaneously growing melanotic 
B16-F10 (in C57BL/6 mice) and amelanotic Melur 
tumors (in SCID mice) 20±2 days after tumor cell 
inoculation. 10-min static PET images were obtained 
90 min after the i.v. injection of 68Ga-NODAGA-PCA. 
Subcutaneously growing B16-F10 tumors were clearly 
visualized in miniPET images with low background 
accumulation (Fig. 4B,C), and after the quantitative 
analysis of the images we found that the 
68Ga-NODAGA-PCA accumulation in melanin 
containing B16-F10 tumor was significantly (p≤0.01) 
higher than in amelanotic Melur tumor (Fig. 4G). 
These in vivo results was correlated with the ex vivo 
biodistribution studies (Table 1), further confirming 
the melanin specificity of 68Ga-NODAGA-PCA. Our 
findings agree with the literature, where 
benzamide-derivatives labeled with PET isotopes (18F, 
68Ga) showed relatively high accumulation in B16 
tumors with excellent tumor-to-background contrast 
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[13-15,28,29]. 
In our study the melanin specificity of 
68Ga-NODAGA-PCA was also investigated in lung 
metastasis mouse model. This syngenic C57BL/6 
animal model is widely used in preclinical melanoma 
research [32,33]. In this present study we developed 
lung metastases by intravenous injection of 1x105 
B16-F10 melanoma cells. By analyzing the 
miniPET/CT images metastatic tumor lesions were 
clearly visualized in the lungs 90 min after 
68Ga-NODAGA-PCA injection (Fig. 6C) with low 
background accumulation. After the quantitative 
evaluation of the PET images approximately 6-8-fold 
higher 68Ga-NODAGA-PCA accumulation was 
observed in B16-F10 metastases than that of the 
background (lung or muscle) uptake. 
Although only moderate accumulation of 
68Ga-NODAGA-PCA was found in either the 
subcutaneously growing B16-F10 tumors (SUVmean: 
0.35±0.09, SUVmax: 2.03±0.87) or lung metastases 
(SUVmean: 0.15±0.04, SUVmax: 0.42±0.06), the low 
activity of other organs allows of high quality images 
with low background activity and high 
tumor-to-muscle or tumor-to-lung ratios. 
Correspondingly, Kim et al. [14] also found that 2 h 
after intravenous injection of 68Ga-SCN-DOTA-PCA 
the tumor-to-muscle ratio was 9.47±2.36, resulting 
high image contrast. 
In other experiments the accumulation of 
68Ga-NODAGA-PCA in experimental melanoma 
tumors was compared to 18FDG by small animal PET 
imaging. 18FDG is frequently used for diagnosis, 
staging, and therapy control of malignances [4,34]. 
However, its non-specific property makes the 
evaluation of the 18FDG-PET images difficult, because 
of the relative high background accumulation in 
metabolically active healthy tissues [8,9]. After the 
intravenous injection of 18FDG for the detection of 
experimental tumors, high accumulation was found 
in both subcutaneously growing amelanotic Melur 
and melanin containing B16-F10 tumors (Fig. 5) and in 
B16-F10 lung metastases (Fig. 6). After the 
quantitative analysis of PET images, B16F-10 
melanoma tumors showed significantly (p≤0.01) 
higher 18FDG uptake than 68Ga-NODAGA-PCA 
accumulation. Despite these evidences, when the 
68Ga-labeled NODAGA-PCA uptake data of the 
tumors were compared to the background (muscle or 
lung) activity, we found these values approximately 
two- or three-fold higher than that of the 18FDG 
uptake ratios. Due to the specific binding to melanin 
and the lower background accumulation, 
68Ga-NODAGA-PCA provided better contrast than 
18FDG. 
Conclusion 
In this study, we report the synthesis of 
68Ga-NODAGA-PCA. Due to its high selectivity and 
strong binding affinity to melanin, favorable 
biodistribution and pharmacokinetics, 
68Ga-NODAGA-PCA might be a potential molecular 
probe for the non-invasive in vivo imaging of 
malignant melanoma tumors and metastases. The 
chelator-PCA adducts can have an additional 
potential – the replacement of the diagnostic 
radiometal with a therapeutic one, these structures 
can serve as theranostics. With this approach, make 
use of low background of non-targeted tissues and 
short effective half-life of these radiotracers, 
PCA-derived radiopharmaceuticals can play an 
important role in the treatment of malignant 
melanomas in the future. 
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